Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.63 |
| ▸ | ITGAV | P06756 | 18/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.63 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.63 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.63 |
| ▸ | RHOA | P61586 | 1/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30073956 | 1.00 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7753126 | 0.92 | ADRA2A (0.58) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| Hydrochloric Acid SCHEMBL7562956 | 0.90 | ADRA2A (0.57) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7752171 | 0.86 | ITGB3 (0.50) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL20245885 | 0.83 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL8541012 | 0.81 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL8537499 | 0.81 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL8538784 | 0.81 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6225174 | 0.81 | ITGB3 (0.50) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL19090485 | 0.81 | KDM4E (0.48) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| CN-115348861-A | Alpha-5 beta-1 inhibitors | 加利福尼亚大学董事会 | 2022-11-15 | — | — | CN | disclosed |
| EP-4072541-A1 | ALPHA-5 BETA-1 INHIBITORS | The Regents of the University of California (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0889875-B1 | CYCLOPROPYL ALKANOIC ACID DERIVATIVES | SEARLE & CO (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1070085-A1 | DUAL A v?b 3? AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS | G.D. SEARLE & CO. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051638-A1 | DUAL Avb3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS | G.D. SEARLE & CO. (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5952381-A | SELECTIVELY INHIBITING OR ANTAGONIZING THE INTEGRINS; ANTITUMOR AGENTS, ANTIARTHRITIC AGENTS, VIRICIDES, MICROBIOCIDES; TREATING OSTEOPOROSIS, SKIN DISORDERS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0889875-A1 | CYCLOPROPYL ALKANOIC ACID DERIVATIVES | G.D. SEARLE & CO. (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5773644-A | INTEGRIN ANTAGONISTS; TREATMENT OF RESTENOSIS, OSTEOPOROSIS, TUMOR METASTASIS | G. D. SEARLE & CO. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036858-A1 | CYCLOPROPYL ALKANOIC ACID DERIVATIVES | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | ITGB3 957/4885ITGAV 1756/4885ITGA2B 1033/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | ITGB3 957/4885ITGAV 1756/4885ITGA2B 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.